Eureka-AI is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Eureka AI

4886 results about "Selenium" patented technology

Selenium is a chemical element with the symbol Se and atomic number 34. It is a nonmetal (more rarely considered a metalloid) with properties that are intermediate between the elements above and below in the periodic table, sulfur and tellurium, and also has similarities to arsenic. It rarely occurs in its elemental state or as pure ore compounds in the Earth's crust. Selenium – from Ancient Greek σελήνη (selḗnē) "Moon" – was discovered in 1817 by Jöns Jacob Berzelius, who noted the similarity of the new element to the previously discovered tellurium (named for the Earth).

Pharmaceutical composition and method for the transdermal delivery of calcium

The present invention relates to a method and transdermal pharmaceutical composition for preventing or reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of calcium and a pharmaceutically acceptable carrier constituting a pluronic lecithin organogel. In addition to calcium, the transdermal pharmaceutical composition may also contain a therapeutically effective amount of: (1) a pharmaceutically acceptably salt of other minerals such as magnesium, zinc, selenium, manganese, or chromium; (2) a vitamin such as vitamin A, vitamin D, vitamin C, vitamin E or B-complex vitamins, choline, lecithin, inositol, PABA, biotin, or bioflavomoids; (3) a carotenoid such as lycopene or lutein; (4) a hormone such as dehydroepiandrosterone, progesterone, pregnenolone, or melatonin; (5) an amino acid such as arginine, glutamine, lysine, phenylalanine, tyrosine, GABA, tryptophan, carnitine, or acetyl-l-carnitine; (6) a fatty acid such as a fish oil or flax seed oil; (7) a vita-nutrient such as coenzyme Q10; (8) a cartilage building nutrient such as glucosamine, chondroitin, or MSM, (9) a herb such as ginkgo biloba, echinacea, 5-HTP, St. John's wort, or saw palmetto; or (9) any combination thereof. The transdermal pharmaceutical composition may be topically administered to a human to prevent or reduce the likelihood of calcium deficiency or imbalances caused by calcium deficiency such as hypertension, high cholesterol, colon and rectal cancer, osteomalacia, rickets, osteoporosis, cardiovascular disease, preeclampsia, tooth decay, and premenstrual syndrome.

Method for preprocessing anode sludge and recovering dissipated metal

The invention relates to a method for pre-processing anode mud and recycling rare metals. The invention carries out pre-processing on the anode mud of copper and lead ions and recycling the rare metals; firstly the anode mud is extracted by an acid liquid; a primary acid extraction liquid and the primary decopper anode mud are obtained by filtering; the primary decopper anode mud after being stirred and grinded with sodium carbonate is extracted by metric acid or acetic acid to obtain the deleading anode mud; after sulfated roasting for steaming selenium is carried out on the primary decopper anode mud or the deleading anode mud, the steaming selenium anode mud is extracted by the acid liquid; a secondary acid extraction liquid and the secondary decopper anode mud are obtained by filtering. The acid extraction liquid recycles the selenium and Te by reducing or recycles the slag of selenium and Te by directly adding alkali to react in the acid extraction liquid. The secondary acid extraction liquid after recycling the Te by reducing uses alkali or adds water to dilute and adjust the pH value of a filter liquid and obtain the slag of bismuth by filtering. The method of the invention has a simple flow, a high recycling rate of selenium, Te and bismuth; the noble metals can be enriched and the recycling rate of gold and silver can be remarkably improved.

Element-negative-ion-releasing sterilizing mite-preventing electromagnetic-wave-preventing fire-retarding nano-grade fabric used in vehicles

The invention relates to element-negative-ion-releasing sterilizing mite-preventing electromagnetic-wave-preventing fire-retarding nano-grade fabric used in vehicles. The invention belongs to the technical field of textile fiber fabric production of vehicle-use nano-grade decorative fabric with functions of refreshing and air-purifying. The fabric is a nano-grade functional healthy textile. The nano-grade fabric provided by the invention is produced form chitosan, which is a natural high polymer extracted from shells of shellfishes, crabs and shrimps; a natural antibiotic humectant SCJ-920; a high-efficiency mite-preventing antibacterial agent SCJ-998; nano-grade negative-ion powder SCJ-900; negative-ion far infrared healthcare slurry 700; a fire retarding finishing agent ATF; an aromatic finishing agent SCM; electromagnetic-wave-preventing ferrites Fe2O3, Fe3O4, and Fe; substances such as TiO2, Al2O3, and ZnO used for providing far infrared radiation; an Ag-embedded nano-TiO2 (AT) antibacterial agent; nano-grade selenium or organic selenium which is rare on earth; organic germanium, Chinese herbal medicines, essential oil, maifanite, tourmaline nano-grade powder and other materials. A mixture of the materials is added to cotton, linen, wool, silk, polyamide fiber, acrylic fiber, terylene or viscose fiber spinning liquid, and the nano-grade fabric is produced through weaving.

Oligomerisation of olefinic compounds with reduced polymer formation

The invention relaters to a process for producing an oligomeric product by oligomerisation of at least one olefinic compound, the process including a) providing an activated oligomerisation catalyst by combining, in any order, i) a source of chromium, ii) a ligating compound of the formula I (R1)mX1(Y) X2 (R2)n. . . . I wherein X1 and X2 are independently an atom selected from the group consisting of nitrogen, phosphorus, arsenic, antimony, bismuth, oxygen, sulphur and selenium or said atom oxidized by S, Se, N or O where the valence of X1 and/or X2 allows for such oxidation, Y is a linking group between X1 and X2, m and n are independently 0, 1 or a larger integer, and R1 and R2 are independently hydrogen, a hydrocarbyl group, an organoheteryl group or a heterohydrocarbyl group, and R1 being the same or different when m>1, and R2 being the same or different when n>1, iii) a catalyst activator or combination of catalyst activators, b) providing a zinc compound, and c) contacting the at least one olefinic compound with a composition containing the activated oligomerisation catalyst and the zinc compound, the zinc compound being present in a sufficient quantity such that the ratio of the molar amount of zinc in the zinc compound to the molar amount of chromium in the source of chromium is between 1 and 10000 The invention also provides for a process for activating an oligomerisation catalyst to be used to produce an oligomeric product from at least one olefinic compound, as described above
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products